Bracco S.p.A. discovers, develops, manufactures, and markets diagnostic imaging agents and solutions for various diagnostic modalities worldwide. It offers contrast agents, administration systems, medical devices, and injectors; prescription drugs, over-the-counter drugs, and food supplements via pharmacies; and oncological anatomopathology advisory, radio-therapeutic treatment, cancer diagnosis, and environmental health and safety services. The company provides customized prevention, diagnosis, rehabilitation, and personalized and therapeutic services. It offers its solutions portfolio for various modalities, including X-ray imaging, magnetic resonance imaging, contrast enhanced ultrasound,...
Via Egidio Folli 50- I
San Donato Milanese, MI 20134
Founded in 1927
Apricus Biosciences, Inc. Launches Vitaros, Topical Treatment for Erectile Dysfunction, or ED, in Italy by Bracco SpA
Sep 8 15
Apricus Biosciences, Inc. has announced the launch of Vitaros, a topical treatment for erectile dysfunction, or ED, in Italy by Bracco SpA. Vitaros, Apricus' novel topical on-demand treatment for erectile dysfunction, or ED, is also marketed under the trademark Vytaros in Belgium and Virirec in Spain. This is the seventh country in the European Union in which the product has been launched, including France, Italy, Germany, the UK, Spain, Belgium and Sweden. In total, Vitaros is currently approved under the European Decentralized Procedure ("DCP") in twenty-two countries, of which fourteen have further approved Vitaros for commercialization at the national phase level of the DCP approval process. As another contributor towards the positive momentum of commercialization by partners, which recently produced 103% growth in units quarter over quarter, Bracco plans to implement a strong promotional strategy targeted at physicians across Italy. In December 2010, Apricus signed an exclusive license agreement with Bracco to market Vitaros, in Italy, Vatican City and San Marino (the "Territory"). Under the terms of the agreement, Apricus has received $1.3 million in up-front and milestone payments from Bracco. Apricus is also eligible to receive milestone payments on future sales, plus double-digit tiered royalties based on Bracco's net sales of the product in the Territory. In exchange, Bracco has the exclusive right to commercialize Vitaros in the Territory. In addition, Bracco has agreed to certain minimum marketing commitments for Vitaros.